Navigation Links
New Proof of Genistein's Efficacy and Safety for Osteopenia and,Osteoporosis Published in Annals of Internal Medicine

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Jun 27, 2007 - Annals of Internal Medicine has published the results of a two-year clinical study on the impact of genistein on bone loss. The paper, "Effects of the Phytoestrogen Genistein on Bone Metabolism in Osteopenic Postmenopausal Women-A Randomized Trial," appears in the current issue (June 19, 2007) and details the safety and efficacy of genistein for the dietary management of osteopenia and osteoporosis. The paper reports a significant gain in bone density among patients taking genistein at both 12 and 24 months over both baseline and placebo.

Key study findings include:

-- Over 85 percent of the women in the study taking genistein showed a gain in bone density.

-- Patients taking genistein in addition to calcium and vitamin D showed a gain in bone density of approximately 3 percent per year over baseline and 6 percent per year over those taking the placebo.

-- No adverse events were reported in the study. All participants were monitored for vasomotor symptoms, vaginal bleeding, breast tenderness, endometrial thickness, depression, irritability, insomnia, and gastrointestinal (GI) symptoms, as well as for changes in hematologic, renal and liver function tests. No changes were noted in any of these parameters except for mild GI symptoms.

Patients in the test group of the study used 54 mg/day of highly purified genistein isolated from soy along with calcium and vitamin D. Principle Investigator for the study, Francesco Squadrito, M.D., Professor of Pharmacology and Head of Clinical Pharmacology, School of Medicine, University of Messina, Italy, explains that there were some interesting aspects to the study: "The placebo in this study was not an inactive pill; instead it was the current standard of care for osteopenia - calcium plus vitamin D. Unlike other research in this area, this study was controlled for soy intake and additional supplem ent use, either of which may confound the results of a study."

The National Osteoporosis Foundation reports that osteoporosis currently afflicts more than 10 million Americans, while an additional 34 million have osteopenia. Osteopenia is the required precursor to osteoporosis. The lack of safe, efficient therapy for osteopenia beyond lifestyle changes with calcium and vitamin D leaves many patients and physicians with a lack of options.

Fosteum, the first prescription product developed to safely meet the nutritional requirements of patients with osteopenia and osteoporosis, is being introduced nationally by Primus Pharmaceuticals, Inc. Fosteum's genistein, which was evaluated in this clinical study, is highly concentrated and cannot be achieved simply through dietary change. According to Dr. Squadrito, "To obtain the amount of genistein found in two capsules of Fosteum, one would have to consume 26 pounds of soybeans or over two gallons of soy milk each day." Since no other product contains the same genistein as found in Fosteum, Dr. Squadrito urges caution in transferring the information in his paper to supplements purporting to contain genistein: "Supplements contain much lower concentrations of genistein and have other, sometimes unidentified, compounds in addition to genistein."

For more information on Fosteum, please visit www.fosteum.com.

About Primus Pharmaceuticals, Inc.

Primus is the first pharmaceutical company to focus on prescription metabolic products dedicated to improving patient quality of life without compromising safety. Primus develops branded prescription drugs and medical foods that are proven safe and effective in chronic or recurring diseases. The Company's needs-based process to develop first-line prescription products formulated to restore metabolic processes at the disease source (rather than masking symptoms) is novel and proprietary. Primus promotes to targeted physician specialists and extends its sale s reach and clinical capabilities through strategic partnerships. All products are protected by composition of matter patents and other intellectual property. Primus is privately held and based in Scottsdale, Ariz. For more information, visit www.primusrx.com.

Fosteum is a prescription medical food product for the clinical dietary management of the metabolic processes of osteopenia and osteoporosis.

Contact

Amendola Communications
Jodi Amendola, 480-664-8412, x11
Mobile: 602-614-3182
Jamendola@ACmarketingPR.com


'"/>




Related medicine technology :

1. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
2. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
3. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
4. Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...
5. Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
6. POZEN Announces Positive Outcome for PA 325 Proof of Concept Study
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
11. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , February 9, 2016 ... gab heute den Abschluss eines Kooperationsvertrags mit ... umfassender Lösungen in den Bereichen Next-Generation-Sequencing (NGS), ... QGEN ; Frankfurt Prime Standard: QIA) gab ... Genomics für die Entwicklung und Förderung umfassender ...
(Date:2/9/2016)... WORCESTER, Mass. , Feb. 9, 2016   ... earned The Joint Commission,s Gold Seal of Approval ® ... continuous compliance with its performance standards. The Gold Seal ... that reflects an organization,s commitment to providing safe and ... --> AllCare Plus Pharmacy underwent a rigorous on-site ...
(Date:2/9/2016)... The leader in accelerated orthodontics, OrthoAccel ® ... the recipient of the 2015 Townie Choice Award in ... medical device that speeds up orthodontic tooth movement by ... associated with treatment, AcceleDent was selected by orthodontists from ... Orthotown survey of the most reliable and reputable ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... United ... In Praise of Prevention,” an animated video designed to prevent the ... translations of the video are being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Brain Preservation Foundation’s (BPF) ... from 21st Century Medicine (21CM) ( http://www.21cm.com/ ), spearheaded by recent MIT ... of an intact rabbit brain for extremely long-term storage using a combination of ...
(Date:2/8/2016)... ... 08, 2016 , ... Coast Dental has a new way to help parents ... and family dentist Yvonne Dorrian, DMD, is hosting a free seminar on Friday, February ... to Target at 1207 North Peachtree Parkway in Peachtree City. Dr. Dorrian will have ...
(Date:2/8/2016)... ... February 08, 2016 , ... Brenton Engineering , ... bags, and flow wrapped products at WestPack 2015, February 9-11, in Anaheim, California. ... up to semi-automatic or fully-automatic case packing with a small footprint, rugged, highly ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... IN metro area, has selected the latest beneficiary of their ongoing community enrichment ... to preventing bullying in area schools. Donations are now being accepted at: ...
Breaking Medicine News(10 mins):